GENE COMPANY
LIVE

Serial Number

79397452

Owner

Gene Company Pty Ltd

Attorney

Michael T. Smith

Filing Date

Mar 14, 2024

Add to watchlist:

No watchlists yet
View on USPTO

GENE COMPANY Trademark

Serial Number: 79397452

GENE COMPANY is a trademark filed by Gene Company Pty Ltd on March 14, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Gene Company Pty Ltd

L11, 307 Queen Street

Entity Type: 99

Trademark Details

Filing Date

March 14, 2024

Registration Date

Not Registered

Goods & Services

Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology, namely, design and testing for new product development; design, engineering, research, and development services in the field of novel RNA nanoparticle technologies for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines

Diagnostic medical, biological, and pharmaceutical preparations for SARS, Flu, MRSA, Dengue, COPD, Idiopathic pulmonary fibrosis, liver failure, liver cancer, NASH, Stroke, Pancreatic cancer, oral squamous cell cancer, Acute myloid leukemia (AML), skin burn, skin scarring, skin aging, eye diseases such as vitreoretinal eye disease, and Macular degeneration, diabetes, obesity for medical laboratory use; vaccines; vaccine adjuvants; DIAGNOSTIC medical, biological, and pharmaceutical preparations for SARS, Flu, MRSA, Dengue, COPD, Idiopathic pulmonary fibrosis, liver failure, liver cancer, NASH, Stroke, Pancreatic cancer, oral squamous cell cancer, Acute myloid leukemia (AML), skin burn, skin scarring, skin aging, eye diseases such as vitreoretinal eye disease, and Macular degeneration, diabetes, obesity for medical use, namely, preparations containing novel RNA nanoparticle technologies; nanoparticle formulations for pharmaceutical, medical or medical diagnostic purposes, namely, RNA packaged lipid and extravesicular nanoparticles; backbone modified conjugated RNAs, drug delivery agents for medical use consisting of RNA nanoparticle formulations that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations comprising drug delivery agents based on RNA nanoparticle formulations; pharmaceutical preparations, namely, RNA and delivery agents comprised of nanoparticle carriers and polymers for the delivery of RNA to human cells

Custom manufacture of pharmaceutical products including manufacture of pharmaceutical preparations containing RNA, nucleic acids, protein nanoparticles; providing information in the field of custom manufacture of pharmaceuticals

Chemical, biological, and bacteriological preparations, other than for medical or veterinary use, for scientific and research use, or for the manufacture of pharmaceuticals; chemical, biological, and bacteriological preparations for scientific and research use, or for the manufacture of pharmaceuticals, namely, preparations containing RNA nanoparticle technologies; RNA nanoparticles, namely, RNA packaged lipid nanoparticles, RNA packaged cell derived extracellular vesicles, chemically modified RNAs capable of naked delivery for scientific, laboratory or medical research use

Filing History

NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 7, 2026 GNFN
FINAL REFUSAL E-MAILED
Apr 7, 2026 GNFR
FINAL REFUSAL WRITTEN
Apr 7, 2026 CNFR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 30, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 12, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 12, 2025 OPNR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 31, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 31, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 31, 2025 TROA
REFUSAL PROCESSED BY IB
Oct 19, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 30, 2024 RFCS
REFUSAL PROCESSED BY MPU
Sep 30, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 26, 2024 RFCR
NON-FINAL ACTION WRITTEN
Sep 25, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 24, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 20, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 20, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 13, 2024 REPR